Gedeon Richter Looks to Dendrite to Enhance its Sales Force Effectiveness Solution

Dendrite International, Inc., (NASDAQ: DRTE) a leading
provider of pharmaceutical industry solutions, today announced the
expansion of its relationship with Gedeon Richter, a leading
pharmaceutical company in Central and Eastern Europe. Dendrite will
provide Gedeon Richter's Russian Federation based division with its
sales force effectiveness (SFE) solution, expanding on a previous
agreement to enhance sales force effectiveness for the company's
divisions in Poland, Romania and the Czech Republic. With the addition
of this division, Dendrite's SFE solution will now assist a total of
1000 of Gedeon Richter's representatives with core sales force
effectiveness enabling functions, including call reporting, targeting,
advanced data sharing, data analysis and decision support, event
management, territory planning and scheduling.
   "We required a solution that gave us the ability to optimize sales
activities across sales forces in multiple countries, with the
versatility to adapt to our growing business. Dendrite was an obvious
choice because it offered the most flexible and scalable solution --
supporting strategic sales forces of under 100 users to more than
1000. Furthermore, since the solution can be deployed in multiple
countries, it gives us the ability to easily share information on a
common platform across all of our Central and Eastern European
regions," said Deputy Commercial Director Beata Taligas at Gedeon
Richter's Budapest headquarters.
   Designed by Dendrite's experts specifically to enhance usability
for pharmaceutical industry sales forces, Dendrite's SFE solution
optimizes and coordinates promotional activities across sales teams,
improves communications, and streamlines new product launches.
   "We are delighted to have extended our offering to Gedeon Richter,
at a time during which the industry is increasingly recognizing the
value of solutions that are easy to use and based on actual business
process flow. Dendrite SFE solutions are built specifically for the
pharmaceutical industry and we look forward to continuing to
strengthen the relationship with Gedeon through adding valuable
support," said Mario Mauri, president, Dendrite Europe.

   About Dendrite

   Founded in 1986, Dendrite International (NASDAQ: DRTE) enables
sales, marketing, clinical and compliance solutions for the global,
pharmaceutical industry. The Company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies. For more information, please visit www.dendrite.com.

   About Gedeon Richter

   Gedeon Richter Ltd carries out research, development, manufacture
and marketing of human finished drugs, active substances and
intermediates. The Company manufactures about one hundred kinds of
pharmaceuticals in more than 170 presentations. Among its products are
original, generic and licensed preparations. Products cover numerous
therapeutic areas, with special emphasis on the production and
development of drugs for the central nervous system, as well as
anti-ulcer agents, cardiovascular and gastrointestinal preparations
and oral contraceptives.

   Note: Dendrite is a registered trademark of Dendrite
International, Inc.

   This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our solutions;
our fixed expenses in relation to fluctuating revenues and variations
in customers' budget cycles; dependence on certain major customers;
changes in demand for our products and services attributable to any
weakness experienced in the economy or mergers, acquisitions and
consolidations in the pharmaceutical industry; successful and timely
development and introduction of new products and versions; rapid
technological changes; increased competition; international
operations; integrating the entities we acquire; our ability to
effectively manage our growth; the protection of our proprietary
technology; our ability to compete in the Internet-related products
and services market; the continued demand for Internet-related
products and services; the ability of our third party vendors to
respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than
anticipated results from strategic relationships; dependence of data
solutions on strategic relationships; events which may affect the U.S.
and world economies; and catastrophic events which could negatively
affect our information technology infrastructure. Other important
factors that should be reviewed and carefully considered are included
in the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in assumptions or other changes affecting such
forward-looking statements.